Franklin Resources Inc. Has $144,000 Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Franklin Resources Inc. reduced its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 68.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 14,801 shares of the company’s stock after selling 32,791 shares during the quarter. Franklin Resources Inc.’s holdings in iTeos Therapeutics were worth $144,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. nVerses Capital LLC increased its holdings in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares during the period. Point72 DIFC Ltd acquired a new stake in iTeos Therapeutics during the third quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. increased its stake in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after acquiring an additional 2,646 shares during the period. Virtu Financial LLC acquired a new position in iTeos Therapeutics in the 3rd quarter valued at $102,000. Finally, Quest Partners LLC lifted its position in shares of iTeos Therapeutics by 914.7% during the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after acquiring an additional 9,934 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ITOS has been the topic of several recent analyst reports. Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of iTeos Therapeutics in a research report on Friday, December 13th. Finally, Wells Fargo & Company lowered their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th.

iTeos Therapeutics Trading Up 2.9 %

NASDAQ:ITOS opened at $7.90 on Friday. iTeos Therapeutics, Inc. has a 12 month low of $7.09 and a 12 month high of $18.75. The stock has a market capitalization of $288.62 million, a price-to-earnings ratio of -2.51 and a beta of 1.37. The firm has a fifty day simple moving average of $8.24 and a two-hundred day simple moving average of $12.11.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.13. Equities analysts predict that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

Insider Activity at iTeos Therapeutics

In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the transaction, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 12.50% of the stock is currently owned by company insiders.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.